Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study

被引：0
|
作者：
Xiangwei Xu
Ruya Li
Peizhen Zhu
Penghai Zhang
Jun Chen
Yongsheng Lin
Yinqiao Chen
机构：
[1] The First People’s Hospital of Yongkang,Department of Pharmacy
[2] People’s Hospital of Jinyun,Department of Pharmacy
[3] The First People’s Hospital of Yongkang,Department of Medical Oncology
来源：
World Journal of Surgical Oncology | / 19卷
关键词：
Advanced non-small cell lung cancer; Maintenance therapy; Chemotherapy; Targeted drug; Prognosis; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Maintenance therapy extended PFS and OS of patients with NSCLC.MT with targeted drugs significantly improved PFS compared with chemotherapy.Longer duration of MT with chemotherapy or targeted drugs prolonged PFS.Patients with adenocarcinomas and NSCLC without distant metastasis gained more OS benefits from MT.Female sex and MT were independent prognostic factors for extended OS.Patients with NSCLC tolerated MT without serious adverse events.
引用
收藏
相关论文
共 50 条
  • [1] Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study
    Xu, Xiangwei
    Li, Ruya
    Zhu, Peizhen
    Zhang, Penghai
    Chen, Jun
    Lin, Yongsheng
    Chen, Yinqiao
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [2] Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Zhang, Kun
    Ma, Xiya
    Gao, Hongjun
    Wang, Hong
    Qin, Haifeng
    Yang, Shaoxing
    Liu, Xiaoqing
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3409 - 3417
  • [3] A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer
    Wang, J.
    Yi, T.
    Dong, Y.
    Ran, R.
    Cao, F.
    Li, Y.
    Luo, Z.
    Xu, Y.
    Fu, Y.
    Kuang, L.
    Chen, G.
    Qu, G.
    Yin, Y.
    Li, J.
    Xu, X.
    Chen, Y.
    Song, Q.
    Chu, Q.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1071 - S1071
  • [4] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Fen Wang
    Feng Jin
    Boran Cheng
    Yue Zhang
    Qing Zhou
    Shubin Wang
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1721 - 1735
  • [5] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen
    Jin, Feng
    Cheng, Boran
    Zhang, Yue
    Zhou, Qing
    Wang, Shubin
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (07) : 1721 - 1735
  • [6] Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
    Li, Jianjie
    Chi, Yujia
    Cao, Guang
    Zhao, Jun
    An, Tongtong
    Wu, Meina
    Wang, Yuyan
    Zhuo, Minglei
    Yang, Xue
    Jia, Bo
    Chen, Hanxiao
    Wang, Jingjing
    Zhai, Xiaoyu
    Wang, Ziping
    [J]. JOURNAL OF THORACIC DISEASE, 2021, 13 (03) : 1813 - 1821
  • [7] Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Zhong, Qiuxia
    Liu, Zhihua
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4115 - 4128
  • [8] The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer
    Wang, F.
    Jin, F.
    Wang, S.
    Zhu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S673 - S673
  • [9] Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
    Ma, Ke
    Guo, Qianqian
    Li, Xingya
    [J]. BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [10] Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study
    Ke Ma
    Qianqian Guo
    Xingya Li
    [J]. BMC Pulmonary Medicine, 23
12345